2010
DOI: 10.1007/s00228-010-0972-5
|View full text |Cite
|
Sign up to set email alerts
|

Effects of multiple-dose pegylated interferon alfa-2b on the activity of drug-metabolizing enzymes in persons with chronic hepatitis C

Abstract: Weekly administration of PEG-IFN alfa-2b to subjects with chronic hepatitis C increased CYP2C8/9 and CYP2D6 activity in some individuals.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
30
0

Year Published

2012
2012
2021
2021

Publication Types

Select...
4
2
2

Relationship

0
8

Authors

Journals

citations
Cited by 14 publications
(30 citation statements)
references
References 17 publications
0
30
0
Order By: Relevance
“…It is however important to note that these patients had significantly lower pretreatment CYP3A4 and CYP2D6 activities than healthy volunteers. Recently also Gupta et al (2011) demonstrated that weekly administration of IFN-α-2b to patients with chronic hepatitis C was associated with small increase in CYP2C8/9 and CYP2D6 activities in some individuals, while there was no effect on CYP3A4 activity and a limited inhibitory effect on CYP1A2. IFN-β treatment in patients with multiple sclerosis revealed unaltered CYP2D6 and CYP2C19 activities (Hellman et al, 2003).…”
Section: Drug Interaction With Therapeutic Proteinsmentioning
confidence: 98%
“…It is however important to note that these patients had significantly lower pretreatment CYP3A4 and CYP2D6 activities than healthy volunteers. Recently also Gupta et al (2011) demonstrated that weekly administration of IFN-α-2b to patients with chronic hepatitis C was associated with small increase in CYP2C8/9 and CYP2D6 activities in some individuals, while there was no effect on CYP3A4 activity and a limited inhibitory effect on CYP1A2. IFN-β treatment in patients with multiple sclerosis revealed unaltered CYP2D6 and CYP2C19 activities (Hellman et al, 2003).…”
Section: Drug Interaction With Therapeutic Proteinsmentioning
confidence: 98%
“…However, there had been reports of PEG-interferon a-2b inhibiting CYP1A2, albeit very mildly. These studies had assessed the effect of PEG-interferon a-2b after approximately 1 month of treatment (Gupta et al, 2011;Brennan et al, 2013), which is much longer than the duration reported for our study. Further, in a parallel arm to our study, PEG-interferon a-2b and ribavirin were administered in an identical regimen in combination with faldaprevir and had no effect on CYP1A2 and CYP2C9 activities .…”
Section: Introductionmentioning
confidence: 88%
“…Although no formal sample size calculations were performed, on the basis of previous drug interaction studies on the pharmacokinetics of interferons (in 7–17 subjects), we considered that 16 subjects should be recruited to this study . The pharmacokinetic characteristics of the five probe drugs in this study were summarized with descriptive statistics, separated into figures obtained before (in the absence of) and after (in the presence of) PEG‐IFN alfa‐2a (40KD).…”
Section: Methodsmentioning
confidence: 99%
“…Interferons are known to down‐regulate drug metabolism by the hepatic cytochrome P450 (CYP) system, and understanding the interactions between PEG‐IFN alfa‐2a (40KD) and co‐administered drugs is of considerable interest. Several studies have evaluated the interactions between conventional (non‐pegylated) interferon and drugs metabolized by various CYP isoenzymes . Although the results are not consistent, the data suggest that conventional interferon may reduce the clearance of theophylline, a substrate of CYP1A2 .…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation